Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials

Journal of Immunotherapy

Volumn 22, Issue 2, 1999, Pages 145-154

  Hernberg, Micaela ^a   Pyrhönen, Seppo ^a   Muhonen, Timo ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Interferon; Melanoma; Metastatic; Odds ratio; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MELANOMA; RANDOMIZED CONTROLLED TRIALS;

EID: 0345040253     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199903000-00006     Document Type: Article

References (52)

1. Thomas H. Balkwill FR. Effects of interferons and other cytokines on tumors in animals: a review. Pharmac Ther 1991:52:307-30.
2. Balkwill F. Interferons. Lancet 1989:1:1060-3.
3. Kirkwood JM. Melanoma: biology of melanoma relevant to biological therapy with interferons. In: DeVita JVT. Heilman S, Rosenberg S, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:388-94.
4. Bajetta E. Di LA. Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994:12:806-11.
5. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995:12:35-40.
6. Falkson CI. Ibrahim J. Kirkwood J. Blum R. A randomized phase III trial of dacarbazine (DTIC) versus DTIC-interferon alfa-2b (IFN) versus DTIC-tamoxifen (tmx) versus DTIC-IFN-tmx in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1996:15:435.
7. Galvez CA. Bonamassa M. Advanced malignant melanoma: DTIC plus rINF-alfa-2b vs. DTIC alone. Eur J Cancer 1991:27(suppl 2): 155.
8. Kirkwood JM. Ernstoff MS, Giuliano A. et al. Interferon alpha-2a and dacarbazine in melanoma. J Nall Cancer Inst 1990:82:1062-3.
9. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993:3: 133-8.
10. Vorobiof D, Falkson G. Voges CW. DTIC versus DTIC and recombinant interferon alfa 2b (rIFNa2b) in the treatment of patients (PTS) with advanced malignant melanoma (MM). 5th European Conference on Clinical Oncology (ECCO-5). Eur J Cancer 1989:25 (abstr.):714.
11. Richne J. Joss RA, Goldhirsch A. Brunner KW. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992;28A: 1044-47.
12. Feun LG. Savaraj N. Moffat F, et al. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 1995:5:273-6.
13. Pyrhönen S. Hahka-Kemppinen M. Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992:10:1919-26.
14. Bafaloukos D, Pavlidis N, Fountzilas G, et al. Recombinant interferon ALFA-2A in combination with carboplatin. vinblastine, and bleomycin in the treatment of advanced malignant melanoma. Am J Clin Oncol 1996;19:296-300.
15. Kokoschka EM. Klocker J. Loicht U. Rehberger A. Macheiner W, Micksche M. Interferon-alpha-carboplatin combination therapy for metastatic melanoma: phase II study [Letter], Eur J Cancer 1994: 30A:2183.
16. Marincola FM. White DF. Wise AP. Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995:13:1110-22.
17. Kruit WH, Goey SH, Calabresi F, et al. Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer 1995;71:1319-21.
18. Dorval T, Negrier S. Chevreau C. et al. Results of a French multicentric randomized trial of chemoimmunotherapy cisplatin (P). 1L-2 (Proleukin). with or without IFN (Roferon) in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1994:13:395 (abstr. 1347).
19. Sparano JA. Fisher RI. Sunderland M. et al. Randomized phase 111 trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993:11:1969-77.
20. Legha SS. Ring S. Bedikian A. et al. Treatment of metastatic melanoma w ith combined chemotherapy containing cisplatin. vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996:7:827-35.
21. Richards JM. Mehta N. Ramming K. Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992:10:1338-43.
22. Atzpodien J. Lopez Hiinninen E. Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine. cisplatin. carmustine and tamoxifen. Eur J Cancer 1995:31 A:876-81.
23. Johnsto SRD. Moore J. Constenla DO, Gore ME. Randomised phase II trial of BCDT Icarmustine (BCNU). cisplatin, dacarbazine (DTIC) and tamoxifen) with or without interferon alpha (IFNa) and interleukin (IL-2) in metastatic melanoma. Ann Oncol (9th National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium on New Drugs for Cancer Therapy). Annals Oncol 1996:7(suppl 1):55.
24. DeKernion JB. Sarna G. Figlin R. Lindner A. Smith RB. The treatment of renal cell carcinoma with human leukocyte alphainterferon. J Urol 1983:130:1063-6.
25. Quesada JR. Swanson DA. Gutterman JU. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J Clin Oncol 1985:3:1086-92.
26. Aulitzky W. Gastl G. Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989:7:1875-84.
27. Ernstoff MS. Nair S. Bahnson RR. et al. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 1990:8:1637-49.
28. Yang JC. Renal cell cancer. In: DeVita JVT. Heilman S. Rosenberg S, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:262-9.
29. Savage P. Muss H. Renal cell cancer. In: DeVita JVT. Heilman S, Rosenberg S. ed. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:373-4.
30. Pyrhonen S, Salminen E, Lehtonen T, et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study (abstr. 614). Proc Am Soc Clin Oncol 1996:15:244.
31. Lissoni P, Barni S. Ardizzoia A, et al. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Titmori 1993:79:397-400.
32. Dexeu FH, Logothetis CJ. Sella A, Finn L. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am. J Clin Oncol 1989;12:350-4.
33. Steineck G. Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990:29:155-62.
34. Atkins MB, Sparano J, Fisher RI. et al. Randomized phase II trial of high dose IL-2 either alone or in combination with interferon alpha-2b (IFN) in advanced renal cell carcinoma (RCCA). Proc Am Soc Clin Oncol Houston, Texas. J Clin Oncol 1991:10:166.
35. Hakansson A, Gustafsson B. Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996:74: 670-6.
36. Hernberg M, Muhonen T, Turunen JP. Hahka-Kemppincn M, Pyrhonen S. The CD4+/CD8+ ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma. J Clin Oncol 1996;14:1690-6.
37. Hernber M. Muhonen T, Pyrhonen S. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma? Ann Oncol 1997:8:71-7.
38. Pierc W, Belldegrun A. deKernion J, Figlin R. Immunotherapy of patients with metastatic renal cell carcinoma (RC’Ca) using tumor infiltrating lymphocytes (TIL) in combination with an outpatient regimen of interleukin-2 (IL-2) with or without interleron-α (IFN-α): UCLA kidney cancer program. Proc Am Soc Clin Oncol 1994:13:238.
39. Mulder NH, van der Gruaf WTA, Willemse PHB. Schraffordt Koops H, de Vries EGE, Sleijfer DT. Dacarbazine (DTIC)-based chemotherapy of patients with disseminated malignant melanoma. Br J Cancer 1994:70:681-3.
40. Otto U, Schneider AW, Conrad S. Klosterhalfen H. Toxicity and efficacy of tumor necrosis factor alone or in combination with alpha-2 interferon in patients with metastatic renal cell carcinoma: results of a clinical phase I/II study. J Urol 1989:141:462.
41. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959:22: 719-48.
42. Miller AB, Hoogstraten B, Staquet M. Winkler A. Reporting results of cancer treatment. Cancer 1981:47:207-14.
43. Vorobiof DA, Bezwoda WR. A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma. Eur J Cancer 1994:30A:797-800.
44. Kriegmai M. Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995:45:758-62.
45. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993:11:661-70.
46. Foon K, Doroshow J. Bonnem E. et al. A prospective randomized trial of alpha-2b-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988:7:540-5.
47. Edsmy F, Esposti PL, Andersson L. Steineck G, Lagergren C, Strander H. Interferon therapy in disseminated renal cell carcinoma. Ratliother Oncol 1985:4:21-6.
48. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol 1996:8:167-74.
49. Falkson CO. Falkson G. Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991: 9:1403-8.
50. Porzsolt F, Digel W, Jacobsen H, Mittnacht S, Kirchner H, Heimpel H. Different antitumor mechanisms of interferon-alpha in the treatment of hairy cell leukemia and renal cell cancer. Cancer 1988:61:288-93.
51. Punt CJA. van Herpen CML, Jansen RLH, Vreugdenhil A, Muller EW, De Mulder PHM. Chemoimmunotherapy with bleomycin, vincristine, lomustine. dacarbazine (BOLD) plus interferon-alpha for metastatic melanoma: a multicentre phase II study. Br J Cancer 1997;76:266-9.
52. Pyrhonen S, Kouri M, Holsti LR, Cantell K. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 1992:49:22-6.